
This interactive tool systematically guides healthcare providers through the complete diagnostic pathway for suspected bullous pemphigoid and provides a comparative overview of leading international treatment guidelines to inform optimal patient management.
In this podcast, Dr. Teri Greiling and Dr. Daniel Butler discuss the enormous burden patients with bullous pemphigoid experience and how our understanding of the disease pathophysiology may help address unmet treatment needs.
Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.

Welcome to the BP learning hub focused on key scientific education on bullous pemphigoid, featuring ADVENT resources.

Drs Donna Culton and Russell Hall explore the Burden of Disease and Diagnosis of BP.
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Enno Schmidt highlights the role of type 2 cytokines involved in the dysregulated Type 2 immune responses that contribute to inflammation and subsequent itch in bullous pemphigoid.
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.